Targeting CBP revers chemoresistance to 5-FU of CDX2/REG4 double-positive gastric cancer

Zhiyuan Fan; Fangyuan Li; Xiao Jiang; Tao Pan; Mingde Zang; Jianfang Li; Beiqin Yu; Qingqing Sang; Wentao Liu; Liping Su; Chen Li; Zhenggang Zhu; Min Yan; Chao Yan; Fei Yuan; Bingya Liu

doi:10.1002/ctm2.70069

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (11) : e70069 DOI: 10.1002/ctm2.70069

LETTER TO THE JOURNAL

Targeting CBP revers chemoresistance to 5-FU of CDX2/REG4 double-positive gastric cancer

Zhiyuan Fan ¹^,²^,³
, Fangyuan Li ¹^,³
, Xiao Jiang ⁴
, Tao Pan ¹^,³
, Mingde Zang ¹^,³^,⁵
, Jianfang Li ¹^,³
, Beiqin Yu ¹^,³
, Qingqing Sang ¹^,³
, Wentao Liu ¹^,³
, Liping Su ¹^,³
, Chen Li ¹^,³
, Zhenggang Zhu ¹^,³
, Min Yan ¹^,³
, Chao Yan ¹^,³^,^†
, Fei Yuan ³^,⁶^,^†
, Bingya Liu ¹^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhiyuan Fan, Fangyuan Li, Xiao Jiang, Tao Pan, Mingde Zang, Jianfang Li, Beiqin Yu, Qingqing Sang, Wentao Liu, Liping Su, Chen Li, Zhenggang Zhu, Min Yan, Chao Yan, Fei Yuan, Bingya Liu. Targeting CBP revers chemoresistance to 5-FU of CDX2/REG4 double-positive gastric cancer. Clinical and Translational Medicine, 2024, 14(11): e70069 DOI:10.1002/ctm2.70069

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sardar AA, Jalal JA, Ameen KSH. Immunohistochemical expression of CDX2 in gastric carcinoma. Iran J Pathol. 2022;17:143-149.

[2]	Naito Y, Oue N, Hinoi T, et al. Reg IV is a direct target of intestinal transcriptional factor CDX2 in gastric cancer. PLoS One. 2012;7:e47545.

[3]	Taylor AM, Côté A, Hewitt MC, et al. Fragment-based discovery of a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor (CPI-637). ACS Med Chem Lett. 2016;7:531-536.

[4]	Wei W, Song Z, Chiba M, et al. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma. Leukemia. 2023;37:396-407.

[5]	Ryan KR, Giles F, Morgan GJ. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. Eur J Haematol. 2021;106:90-99.

[6]	Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12:4935-4948.

[7]	Koh I, Nosaka S, Sekine M, Sugimoto J, Hirata E, Kudo Y. Regulation of REG4 expression and prediction of 5-fluorouracil sensitivity by CDX2 in ovarian mucinous carcinoma. Cancer Genomics Proteomics. 2019;16:481-490.

[8]	Weinert BT, Narita T, Satpathy S, et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell. 2018;174:231-244.

[9]	Deng W, Wang C, Zhang Y, et al. GPS-PAIL: prediction of lysine acetyltransferase-specific modification sites from protein sequences. Sci Rep. 2016;6:39787.

[10]

Chakraborty S, Senyuk V, Sitailo S, Chi Y, Nucifora G. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles. J Biol Chem. 2001;276:44936-44943.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.